MedPath

Integrating PrEP Decision Making Into Counseling in Sexual and Reproductive Health Clinics

Not Applicable
Not yet recruiting
Conditions
Sexual Risk Behavior for HIV-infection
Reproductive Health
Registration Number
NCT06684613
Lead Sponsor
Yale University
Brief Summary

This study addresses the need for HIV prevention to be integrated into counseling visits at sexual and reproductive health clinics.

Detailed Description

The purpose of this study is to expand and enhance a PrEP decision aid to include the full array of available formulation options and then integrate its delivery into sexual and reproductive health settings during counseling visits, where PrEP can be provided to all women who are interested. Rooted in health implementation frameworks, this study evaluates health and implementation determinants simultaneously along: 1) innovation characteristics; 2) clinical encounter; 3) recipients; and 4) context.

In Aim 1, patients (n=15-20), clinicians (n=10), and staff (n=10) at sexual and reproductive health clinics across Greater New Haven, CT will be engaged for semi-structured interviews to expand and enhance an existing PrEP decision aid to include all available formulations and optimize its integration into sexual and reproductive health clinics. Qualitative interviews will inform infrastructure development to support PrEP delivery in sexual and reproductive health clinics.

In Aim 2 (a hybrid Type 2 effectiveness-implementation study), patients will be randomized (n=50) to receive either the PrEP decision aid or generic PrEP information prior to a clinician visit. In follow-up interviews immediately post-visit, and at Months 3 and 6, primary outcomes are clinical efficacy (PrEP initiation) and implementation (using Proctor definitions for feasibility, acceptability, penetration, and adoption) that are important for future planned scale-up.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
Female
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
PrEP initiation (prescribing)6 months

Whether PrEP was prescribed (yes/no) in the EHR within the 6-month time frame

Feasibility of implementing the enhanced PrEP decision aid in SRH settings, according to the Proctor taxonomy6 months

Feasibility is defined as the extent to which the enhanced PrEP decision aid can be successfully used in SRH clinic settings (qualitative).

Acceptability of the enhanced PrEP decision aid within SRH settings, according to users (Proctor taxonomy)6 months

Acceptability is defined as the user perception that the enhanced PrEP decision aid is acceptable in SRH settings.

Penetration (reach) of the enhanced decision aid within SRH clinics (Proctor taxonomy)6 months

Penetration (reach) of the intervention, measured by reasons for not meeting inclusion criteria

Adoption of the enhanced PrEP decision aid within SRH settings, according to users (Proctor taxonomy)6 months

Adoption of the enhanced decision aid into SRH clinics, assessed by whether PrEP was discussed during the visit (yes/no)

Secondary Outcome Measures
NameTimeMethod
PrEP initiation (dispensing)6 months

Whether PrEP was dispensed (yes/no) in the EHR within the 6-month time frame

PrEP initiation (first use)6 months

Whether PrEP was started by the patient within the 6 months' time frame (yes/no)

PrEP adherence6 months

Pharmacokinetic: (objective) urine tenofovir levels (units detected/ not detected)

PrEP persistence6 months

Dates of completed PrEP encounters in EHR (i.e., clinic dates)

Trial Locations

Locations (1)

Yale Clinical and Community Research

🇺🇸

New Haven, Connecticut, United States

Yale Clinical and Community Research
🇺🇸New Haven, Connecticut, United States
Carolina Price, MPA
Contact
203-499-8075
carolina.price@yale.edu
Jaimie P Meyer, MD
Principal Investigator
Sangini S Sheth, MD
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.